The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...

She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...

A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...

AstraZeneca (AZN) has reported positive results from an analysis of its NIAGARA Phase 3 study of Imfinzi in the treatment of ...

AstraZeneca’s ( www.AstraZeneca.com) flagship health equity programme - Healthy Heart Africa (HHA), marks its 10th ...

Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s (AZN) IMFINZI, administered ...

A class action lawsuit was filed against AstraZeneca Plc (AZN) by Levi & Korsinsky on December 23, 2024. The plaintiffs ...

AstraZeneca is expecting Phase III trial data for seven new medicines in 2025, its CEO said as he confirmed the company’s ...

Havant MP Alan Mak has demanded to know why the Labour Government chose to walk away from a £450m investment deal with ...

AstraZeneca’s share price has dropped recently on concerns relating to its Chinese operation, but this may have left the ...

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...